Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily

被引:23
作者
Emberton, M
Elhilali, M
Matzkin, H
Harving, N
van Moorselaar, J
Hartung, R
Alcaraz, A
Vallancien, G
机构
[1] McGill Univ, Dept Urol, Montreal, PQ, Canada
[2] UCL, Dept Urol, London, England
[3] Tel Aviv Med Ctr & Sch Med, Dept Urol, Tel Aviv, Israel
[4] Aalborg Hosp, Dept Urol, Aalborg, Denmark
[5] Univ Utrecht, Med Ctr, Dept Urol, Utrecht, Netherlands
[6] Tech Univ Munich, Dept Urol, D-8000 Munich, Germany
[7] Fdn Puigvert, Dept Urol, Barcelona, Spain
[8] Inst Mutualiste Montsouris, Dept Urol, Paris, France
关键词
D O I
10.1016/j.urology.2005.03.024
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To assess the predictors of acute urinary retention (AUR) and/or surgery related to benign prostatic hyperplasia (BPH) in 3514 men complaining of lower urinary tract symptoms and treated for 6 months with the selective alpha(1)-blocker alfuzosin at 10 mg once daily. Methods. The impact of baseline (age, prior AUR, prostate-specific antigen tertiles, lower urinary tract symptoms severity, and bother score) and dynamic (international Prostate Symptom Score [IPSS] worsening of 4 points or greater and bother greater than 3 during treatment) variables on the risk of AUR/BPH-related surgery was assessed using Kaplan-Meier curves and log-rank tests. Associated hazard ratios (HRs) and 95% confidence intervals (Cis) were calculated using Cox proportional hazard models. Results. Of the 3514 men analyzed, 140 (4%) experienced a first episode of conservatively managed AUR before inclusion. Of those 140 men, 5 (3.6%) had AUR relapse during alfuzosin treatment and 6 (4.3%) underwent BPH-related surgery. Of those 3374 men without prior AUR, 19 (0.6%) experienced AUR during treatment and 41 (1.2%) underwent BPH-related surgery. During treatment, the most important predictors of AUR were prior AUR (HR 6.35, 95% Cl 2.31 to 17.40; P <0.0 1), IPSS worsening of 4 or greater (HR 3.34, 95% Cl 1.1 1 to 9.99; P = 0.03), and bother score greater than 3 (HR 3.32, 95% Cl 1.29 to 8.53; P <0.0 1) at endpoint. Other variables (age, PSA, baseline IPSS, and bother) had much less predictive value. Similar results were observed regarding the risk of AUR and/or BPH-related surgery. Conclusions. The results of this 6-month real life practice study suggest that prior AUR and symptom deterioration during treatment with alfuzosin 10 mg once-daily (IPSS worsening of 4 or more points, bother score greater than 3) were the strongest predictors of AUR and AUR/BPH-related surgery in men with lower urinary tract symptoms.
引用
收藏
页码:316 / 322
页数:7
相关论文
共 14 条
[2]   EAU guidelines on benign prostatic hyperplasia (BPH) [J].
de la Rosette, JJMCH ;
Alivizatos, G ;
Madersbacher, S ;
Perachino, M ;
Thomas, D ;
Desgrandchamps, F ;
De Wildt, M .
EUROPEAN UROLOGY, 2001, 40 (03) :256-263
[3]   Benign prostatic hyperplasia: A progressive disease of aging men [J].
Emberton, M ;
Andriole, GL ;
de la Rosette, J ;
Djavan, B ;
Hoefner, K ;
Navarrete, RV ;
Nordling, J ;
Roehrborn, C ;
Schulman, C ;
Teillac, P ;
Tubaro, A ;
Nickel, JC .
UROLOGY, 2003, 61 (02) :267-273
[4]   Fortnightly review - Acute urinary retention in men: an age old problem [J].
Emberton, M ;
Anson, K .
BMJ-BRITISH MEDICAL JOURNAL, 1999, 318 (7188) :921-925
[5]   Natural history of prostatism: Risk factors for acute urinary retention [J].
Jacobsen, SJ ;
Jacobson, DJ ;
Girman, CJ ;
Roberts, RO ;
Rhodes, T ;
Guess, HA ;
Lieber, MM .
JOURNAL OF UROLOGY, 1997, 158 (02) :481-487
[6]  
Kaplan SA, 2003, J UROLOGY, V169, P332
[7]   Distribution of post-void residual urine volume in randomly selected men [J].
Kolman, C ;
Girman, CJ ;
Jacobsen, SJ ;
Lieber, MM .
JOURNAL OF UROLOGY, 1999, 161 (01) :122-127
[8]  
McConnell JD, 2003, J UROLOGY, V169, P332
[9]   The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia [J].
McConnell, JD ;
Roehrborn, CG ;
Bautista, OM ;
Andriole, GL ;
Dixon, CM ;
Kusek, JW ;
Lepor, H ;
McVary, KT ;
Nyberg, LM ;
Clarke, HS ;
Crawford, ED ;
Diokno, A ;
Foley, JP ;
Foster, HE ;
Jacobs, SC ;
Kaplan, SA ;
Kreder, KJ ;
Lieber, MM ;
Lucia, MS ;
Miller, GJ ;
Menon, M ;
Milam, DF ;
Ramsdell, JW ;
Schenkman, NS ;
Slawin, KM ;
Smith, JA ;
Kusek, JW ;
Nyberg, LM ;
Briggs, JP ;
McConnell, JD ;
Crawford, ED ;
Homan, K ;
Donohue, R ;
Parker, D ;
Easterday, K ;
Robertson, K ;
Kaplan, S ;
Wentland, M ;
Hardy, L ;
Roehrborn, C ;
Ahrens, A ;
McConnell, J ;
Hall, D ;
Cutts, D ;
Carter, S ;
Waldrep, K ;
Schenkman, N ;
Sanetrik, K ;
Sihelnik, S ;
Zorn, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (25) :2387-2398
[10]   Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia [J].
Roehrborn, CG ;
McConnell, JD ;
Lieber, M ;
Kaplan, S ;
Geller, J ;
Malek, GH ;
Castellanos, R ;
Coffield, S ;
Saltzman, B ;
Resnick, M ;
Cook, TJ ;
Waldstreicher, J .
UROLOGY, 1999, 53 (03) :473-480